Accession Number:

AD1095849

Title:

Targeting Basal Breast Cancer

Descriptive Note:

Technical Report,01 Sep 2017,31 Aug 2018

Corporate Author:

New York University School of Medicine New York United States

Personal Author(s):

Report Date:

2018-09-01

Pagination or Media Count:

22.0

Abstract:

We hypothesized that Gpr is a highly specific marker of mammary stem cells or early progenitors that become amplified in basal type tumors and that elimination of Gpr cells will lead to tumor regression and eradication. To test these hypothese we aimed to 1 identify, isolate and characterize Gpr cells, determine their potency by tracing their lineage, and kill Gpr cells and monitor the effect on mammary development and 2 determine Gpr expression in human breast cancer, and test if ablating Gpr cells affects tumorigenesis in murine mammary tumors. In this grant period we have 1 characterized Gpr expression using lac Z reporters, 2 generated Gpr null mice and documented their mammary and eye developmental defects, 3 genetically demonstrated a requirement for the Gpr cytoplasmic and transmembrane domains, 4 begun to track the Gpr lineage by crossing a mouse where the Gpr promoter drives expression of a tamoxifen induced cre recombinase to an inducible R26R-TdTomato reporter line.

Subject Categories:

  • Medicine and Medical Research
  • Anatomy and Physiology
  • Biochemistry

Distribution Statement:

APPROVED FOR PUBLIC RELEASE